Vaccines Bioprocess Development and Commercialisation
Discover vaccine development, commercialisation and regulatory requirements.
University College London in collaboration with the Massachusetts Institute of Technology (MIT) is announcing its Vaccines Bioprocess Development & Commercialization Workshop for 23rd-25th June 2015.
Vaccines represent a challenging area of development. There are many antigen designs and expression systems, all of which impact on the upstream and downstream process steps. This course seeks to use a combination of lectures and case studies to allow delegates to appreciate the different scale-up strategies within the complex regulatory framework for these multifarious biologics.
A team of outstanding international experts has agreed to join us in exploring the issues related to process development, regulation and commercialization of new vaccine products. The speakers will be available during for course for direct discussion and networking opportunities.
Speakers from MedImmune, MIT, Pfizer, Protein Sciences, GE Healthcare and GSK will focus on the key technical aspects critical for success and integrate those with an understanding of the regulatory environment.
The early draft programme can be found on our partners website.
This meeting will be located at the MIT campus in Cambridge, MA (USA). The closest airport is Boston Logan Airport and is a short 30 minute drive to the meeting location.
The course is priced at $2485. Register by 1st March for the Early Bird rate of $1988.
For more information or to book a place, please email email@example.com.
- London - 5th-7th December, 2012
- India - 23rd-25th September, 2013
- Portugal - 14th-16th April, 2014 at iBET
- USA - 23rd-25th June, 2015 at MIT
Who should attend?
- Specialised vaccines staff who would benefit from broadening their knowledge base
- Those new to vaccine development (recent graduates / research scientists)
- Project Managers, funders and policy-makers wanting to gain an understanding in vaccines.
Questions? E-mail firstname.lastname@example.org for further information.
Page last modified on 16 feb 15 15:23